- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07593170
AKK Study in Improving Obesity and Metabolic Status in Children and Adolescents
A Randomized, Double-blind, Placebo-controlled Study of Akkermansia Muciniphila AKK PROBIO in Improving Obesity and Metabolic Abnormalities in Children and Adolescents Aged 7-18 Years
The problem of obesity among children and adolescents is becoming increasingly serious and may affect their health in adulthood. Researches have found that a type of probiotic in the intestinal tract - "Akkermansia muciniphila" (referred to as AKK), may help regulate metabolism and weight. Although it has shown effects in adults, its safety and efficacy in children and adolescents still need further verification.
This study aims to evaluate the effects of supplementing Akkermansia Muciniphila AKK PROBIO on weight, metabolic health and intestinal flora of obese children and adolescents aged 7 to 18.
연구 개요
상태
개입 / 치료
상세 설명
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Qian Lin, Doctor
- 전화번호: +86 13874820173
- 이메일: linqian@csu.edu.cn
연구 연락처 백업
- 이름: Hongmei Zhao
- 전화번호: +86 13975105334
- 이메일: 364875977@qq.com
연구 장소
-
-
Hunan
-
Changsha, Hunan, 중국
- Xiangya School of Public Health
-
연락하다:
- Qian Lin, Doctor
- 전화번호: +86 13874820173
- 이메일: linqian@csu.edu.cn
-
연락하다:
- Chuxin Wang, Bachelor
- 전화번호: +86 15367802575
- 이메일: 45100409@qq.com
-
부수사관:
- Di Zhu, Bachelor
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 어린이
- 성인
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Age range: 7 years old to 18 years old (inclusive of boundary values), gender not restricted.
- Primary obesity: According to the WS/T 586-2018 standard issued by the National Health Commission of China, or the internationally recognized CDC/WHO standard, diagnosed as obesity (if BMI ≥ the 95th percentile of children of the same age and gender).
- The subjects and their legal guardians understand the research content, voluntarily participate and sign the written informed consent form (for guardians), and the informed consent form (for children aged 8 years and above).
- Able to comply with the research protocol, complete all visits and sample collection.
Exclusion Criteria:
- Have a definite endocrine disorder causing obesity (such as Cushing's syndrome, hypothyroidism), a genetic syndrome (such as Prader-Willi syndrome), or other known organic diseases.
- Have a severe primary disease of the liver, kidney, cardiovascular system, respiratory system or hematopoietic system, etc.
- Have used antibiotics, probiotics, prebiotics or synbiotic products within 3 months prior to screening.
- Have a history of systemic use of glucocorticoids or other drugs that may affect weight and metabolism (such as metformin, systemic glucocorticoids, diuretics, etc.) within 1 month prior to screening.
- Subjects are allergic to any component of the study product (AKK probiotic capsules or placebo).
- Subjects are participating in other clinical trials.
- Have a history of severe gastrointestinal diseases, such as inflammatory bowel disease (IBD).
- Other conditions as determined by the researcher to be unsuitable for participation in this study.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
위약 비교기: Placebo Group
Placebo group (n=50): The subjects took one placebo capsule (containing inert ingredients such as maltodextrin) identical in appearance and taste to the AKK probiotic capsules before each breakfast and dinner every day for 12 consecutive weeks. After the study ended, the subjects in the placebo group could receive the same dose and specification of AKK probiotic capsules. Basic intervention: During the study period, both groups of subjects would receive unified and standardized health education, including the principles of balanced diet provided by registered dietitians and the physical activity suggestions provided by exercise rehabilitation specialists. |
Placebo group (n=50): The subjects took one placebo capsule (containing inert ingredients such as maltodextrin) identical in appearance and taste to the AKK probiotic capsules before each breakfast and dinner every day for 12 consecutive weeks.
After the study ended, the subjects in the placebo group could receive the same dose and specification of AKK probiotic capsules.
|
|
실험적: AKK Group
This intervention trial intends to use pasteurized AKK PROBIO, with each dose containing the equivalent of 30 billion inactivated bacterial cells. AKK PROBIO is a research hotspot in the field of intestinal microecology. The pasteurized AKK PROBIO (belonging to prebiotics) have been proven to have good safety and metabolic improvement effects in adults. Compared to live bacterial preparations, the inactivated form has higher stability, a longer shelf life, and better safety. AKK group (n=50): The subjects take one AKK probiotic capsule orally before each breakfast and dinner every day, and the intervention lasted for 12 weeks. During the study period, both groups of participants will receive unified and standardized health education, which includes the principles of balanced diet provided by registered dietitians and the suggestions for physical activities provided by exercise rehabilitation specialists. |
This intervention trial intends to use pasteurized AKK PROBIO, with each dose containing the equivalent of 30 billion inactivated bacterial cells.
AKK PROBIO is a research hotspot in the field of intestinal microecology.
The pasteurized AKK PROBIO (belonging to prebiotics) have been proven to have good safety and metabolic improvement effects in adults.
Compared to live bacterial preparations, the inactivated form has higher stability, a longer shelf life, and better safety.
AKK group (n=50): The subjects take one AKK probiotic capsule orally before each breakfast and dinner every day, and the intervention lasted for 12 weeks.
During the study period, both groups of participants will receive unified and standardized health education, which includes the principles of balanced diet provided by registered dietitians and the suggestions for physical activities provided by exercise rehabilitation specialists.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Z - score
기간: During the baseline period (T0), the middle period (T1, 6 weeks), and the end of the intervention (T2, 12weeks)
|
The Z-score for children (Z-score) is a statistical indicator that measures the deviation of children's growth indicators such as height (in meters), weight (in kilograms), and BMI (in kg/m^2) from the reference population of the same age and gender. It is used to assess nutritional status and growth development levels. The nutritional status can be judged by evaluating the height-for-age z-score (HAZ), weight-for-age Z-score (WAZ), and weight-for-height z-score (WHZ) of children and BMI-for-age Z-score (BMIZ). The Z-score formula is: Z = (Measured value - Average value of the reference population) / Standard deviation of the reference population. Standard: ±2 : Normal range (95% healthy children)
|
During the baseline period (T0), the middle period (T1, 6 weeks), and the end of the intervention (T2, 12weeks)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Dietary intake
기간: At the baseline (T0), mid-term (T1, 6weeks), and the end of the intervention (T2, 12weeks)
|
The dietary intake of the research subjects was understood through 24-hour recall and food frequency questionnaires (for the past month). The dietary and nutrient intake of the research subjects was evaluated through food diversity scores and the intake of energy and nutrients(converts the weekly intake volume (ml/g) into "servings per week"). A designed dietary frequency questionnaire was used to evaluate the regular and environmental dietary behaviors of adolescents in the past three months. The questionnaire is based on common dimensions of dietary behavior and mainly covers five core behavioral categories: having breakfast, having a late-night snack, having meals at school, eating alone, and using food delivery platforms. The frequency options for each category are "Never", "once a month or less", "2 to 3 times a month", "once a week", "2 to 3 times a week", "4 to 5 times a week", "once a day", "twice a day", and "three or more times a day". |
At the baseline (T0), mid-term (T1, 6weeks), and the end of the intervention (T2, 12weeks)
|
|
Sleep quality (13- 18 years)
기간: At the baseline period (T0), mid-term (T1, 6weeks), and the end of the intervention (T2, 12weeks)
|
The Pittsburgh Sleep Quality Index (PSQI) in Chinese was used to assess the subjective sleep quality of participants aged 13 to 18 years. This scale consists of 19 self-rated items and 5 other-rated items, and the scoring can yield 7 scoring items including sleep latency, sleep disorders, sleep quality, sleep duration, hypnotic drugs, sleep efficiency and daytime function. Each component score of the PSQI ranges from 0 to 3, with 3 indicating the greatest dysfunction or disturbance. The seven component scores are then summed to obtain a global PSQI score, which ranges from 0 to 21. Higher scores indicate poorer sleep quality, with a score greater than 5 suggesting significant sleep difficulties. The evaluation of different dimensions of the scale will be separately described. |
At the baseline period (T0), mid-term (T1, 6weeks), and the end of the intervention (T2, 12weeks)
|
|
Sleep quality (7- 12 years)
기간: At the baseline period (T0), mid-term (T1, 6weeks), and the end of the intervention (T2, 12weeks)
|
For children aged 7 to 12 years, the sleep questionnaire items were designed based on the CSHQ (Children's Sleep Habits Questionnaire). It consists of 48 items (33 scoring items), and can assess specific sleep problems in eight aspects: poor sleep habits, sleep anxiety, irregular sleep duration, sleep breathing disorders, abnormal sleep patterns, daytime sleepiness, night awakenings, and prolonged sleep latency. CSHQ requires parents to recall their child's sleep patterns over the past 4 weeks, and to select the sleep condition that best represents the typical week for a 3-point Likert scale rating of "often" (5-7 times per week), "sometimes" (2-4 times per week), and "rarely" (0-1 time per week). |
At the baseline period (T0), mid-term (T1, 6weeks), and the end of the intervention (T2, 12weeks)
|
|
Gastrointestinal symptoms
기간: At the baseline period (T0), mid-term (T1, 6weeks), and the end of the intervention (T2, 12weeks)
|
Gastrointestinal symptoms will be evaluated using the Gastrointestinal Symptom Rating Scale (GSRS). The GSRS is a specific scale consisting of 15 items , with each item scored from 1 (no symptoms at all) to 7 (extremely severe symptoms). The GSRS was used to assess the occurrence of gastrointestinal symptoms in the subjects over the past week, covering five types of digestive tract symptoms: reflux syndrome, abdominal pain syndrome, dyspepsia, diarrhea syndrome, and constipation syndrome. The total score is the sum of all items, with a higher score indicating a more severe condition. |
At the baseline period (T0), mid-term (T1, 6weeks), and the end of the intervention (T2, 12weeks)
|
|
Stool Classification
기간: At the baseline period (T0), mid-term (T1, 6weeks), and the end of the intervention (T2, 12weeks)
|
The Bristol Stool Classification Scale (BSFS) was used to evaluate the type of stool. The BSFS is a widely used scale for assessing intestinal motility and can be used to understand the type of stool of the subjects over the past week. This scale presents the transformation from hard stool to watery stool through pictures of types one to seven. The seven types of stool are: Type 1: Separate hard lumps, like nuts (difficult to pass) Type 2: Sausage-shaped, but lumpy Type 3: Like a sausage but with cracks on its surface Type 4: Like a sausage or snake, smooth and soft (average stool) Type 5: Soft blobs with clear cut edges Type 6: Fluffy pieces with ragged edges, a mushy stool (diarrhea) Type 7: Watery, no solid pieces, entirely liquid (diarrhea) |
At the baseline period (T0), mid-term (T1, 6weeks), and the end of the intervention (T2, 12weeks)
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Qian Lin, Doctor, Xiangya School of Public Health, Central South University
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- HCHLL2026153
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
Placebo (maltodextrin)에 대한 임상 시험
-
Ball State University모병
-
Jacksonville State University완전한인지 기능 | 혐기성 성능 | Resistance Exercise Performance | Dietary Supplementation Athletic Performance미국
-
RDC Clinical Pty Ltd완전한
-
Second Affiliated Hospital, School of Medicine,...모병
-
Newish Biotech (Wuxi) Co., Ltd.아직 모집하지 않음
-
Chiesi Farmaceutici S.p.A.아직 모집하지 않음
-
Nature's Sunshine Products, Inc.아직 모집하지 않음
-
Yale UniversityHartford HealthCare아직 모집하지 않음